Abivax - ADR

XNAS:ABVX 4:00:00 PM EDT

121.48

-4.32 (-3.43%)

4:15:47 PM EDT: $121.15 -0.33 (-0.27%)

Market Cap (Intraday)	9.63B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.4 Million
Adjusted EPS	-$0.93

See more estimates

10-Day MA	$120.64
50-Day MA	$118.48
200-Day MA	$96.18

See more pivots

Abivax - ADR Stock, XNAS:ABVX

7-11 Boulevard Haussmann, Paris, Ile-de-France 75009

France

Phone: +33.1.53.83.09.63

Number of Employees: 61

http://www.abivax.com

Description

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.